Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 124 publications
An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response.
Journal: Journal of the Canadian Association of Gastroenterology
Published: June 05, 2026
Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.
Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.
Journal: International archives of allergy and immunology
Published: May 16, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.
Journal: Journal of Crohn's & colitis
Published: March 24, 2026
Eosinophilic Esophagitis following Oral Immunotherapy: A Systematic Review and Meta-Analysis.
Journal: International archives of allergy and immunology
Published: March 12, 2026
Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN).
Journal: Rheumatology and therapy
Published: February 18, 2026
The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.
Journal: Alimentary pharmacology & therapeutics
Published: January 05, 2026
Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project.
Journal: Journal of the Canadian Association of Gastroenterology
Published: December 15, 2025
Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: November 07, 2025
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.
Journal: The American journal of gastroenterology
Published: October 15, 2025
Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars.
Journal: World journal of gastroenterology
Published: September 28, 2025
Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease.
Journal: World journal of gastroenterology
Published: September 17, 2025
Last Updated: 09/26/2026